With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

CKD and ESRD can have unpleasant cutaneous manifestations, including alopecia, but there are several helpful approaches to mitigating hair loss.

BRP, identified through peptide prediction, may revolutionize weight loss treatment, offering efficacy without the ...

Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ingredient in its weight-loss drugs Ozempic and Wegovy, to lower heart risks.

They’re expensive and aren’t a short-term fix, but Ozempic and Wegovy show great promise in regulating weight. | Opinion ...

Still, since Ozempic was approved in 2017, thousands of studies have been published examining the effects of GLP-1s. Last ...

Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat alcohol use disorder and alcohol-associated liver disease.

Kennedy Jr., who was tapped to lead the Department of Health and Human Services for the Trump administration, recently ...

Weight loss drugs like Ozempic deliver more health benefits than expected.

Some early evidence also suggests GLP-1-based weight-loss drugs such as Wegovy, Ozempic, Mounjaro ... eye conditions like ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.